chrisvoncsefalvay/vaers-outcomes huggingface dataset:
actually got covid in between the 1st and the 2nd dose; sore throat; had a fever; he lost his taste and smell; he lost his taste and smell; This is a spontaneous report from a contactable consumer or other non hcp (patient).  The 19-year-old male patient received first dose of BNT162B2 (Formulation: Solution for injection, Batch/Lot number: EN6207 Expiration Date: unknown), via an unspecified route of administration, administered in Arm Left on 14Mar2021 10:00 (Age at vaccination 19 years) as DOSE 1, SINGLE for covid-19 immunization. The patient had no medical history, no relevant family medical history and was not on concomitant medications. He started experiencing symptoms on 19Mar2021, which was 10 days prior to this report. It was stated his symptoms were sore throat, had a fever at some point that went away and the worst symptom was that he lost his taste and smell. On 24Mar2021, the patient was diagnosed with Covid, it was stated that actually got Covid in between the first and the second dose. The patient underwent laboratory tests and procedures on 23Mar2021 which included SARS-COV-2 TEST: result was found positive on 24Mar2021. He received no treatment for events. No additional vaccines were administered on Same date of the Pfizer Suspect. The patient did not visit to emergency room. He did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was stated the only symptom left that he had was that the taste and smell were present but the other symptoms were gone and he knew it would take a while for taste and smell to come back. Description of complaint: He has not yet had the second dose of the Pfizer Vaccine but it was scheduled for 10Apr2021. It was stated that his second dose of the Pfizer Vaccine was scheduled for next Sunday but he pushed the appointment back to 10Apr2021 and stated this was still in the 28 day window to have the second dose. It was stated that he was out of quarantine on the day of this report and had no fever and had nothing and was all healed. He had no treatment for the reported event. The events of sore throat, fever, was resolved on an unknown date in 2021. The outcome of event actually got COVID in between the first and the second dose was unknown; however, the outcome of the events of lost his taste and smell was reported as not resolved.  His patient card had no expiry date or NDC to provide.   No follow up attempts were possible. No further information was expected.
Arm swelled, itched, got hot & red. Got a migraine, nausea, & lack of energy. These symptoms lasted 2 days. Swelling & redness increased to 3/4 diameter of arm & lasted 5 days.
Per caller his friend and wife received the Pfizer COVID-19 Vaccine and tested positive for COVID 4 days after the first vaccine; This is a spontaneous report from a Pfizer-sponsored program  and medical information team. A contactable physician reported that an 80-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunization. The patient's medical history was not reported. Concomitant medication included bamlanivimab (Bamlan back in January) from an unspecified date in Jan2021. Per caller his friend and wife received the Pfizer COVID-19 Vaccine and tested positive for COVID 4 days after the first vaccine. They were instructed at the vaccine site they would need to restart the vaccine series. Caller asking if that's correct or not. The patient underwent lab test and procedure which included COVID: Positive on an unspecified date. The outcome of the event was unknown.   No follow-up attempts are needed; Information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021440873 Same reporter/drug/AE, different patients
cOVID POSITIVE ON 1/26/2022. Discharge Diagnosis: Principal Problem:   Acute renal failure Active Problems:   HTN (hypertension)   DM (diabetes mellitus)   Urinary tract infection with hematuria   Urinary retention due to benign prostatic hyperplasia   Ureterolithiasis   Pneumonia, bacterial   COVID-19 virus infection        Hospital Course: Patient is a 75 y.o. male admitted with aki 2/2 dehydration. Improved with ivf. Had uti and renal stone. Abx given. Seen by urology for right jj ureteral stent, cystoscopy. Covid-19 pna, negative on admission but then positive on retest while admitted, completed remdesivir / abx.  Deconditioning noted and snf placement found by sw. On room air, recovered from acute disease.                Physical Exam on the Date of Discharge: Vitals: Blood pressure 102/60, pulse 58, temperature 98 °F (36.7 °C), temperature source Oral, resp. rate 18, height 5' 11" (180.3 cm), weight 52 kg (114 lb 11.2 oz), SpO2 97 %.  General Appearance: alert, NAD Lungs:  normal effort Heart: S1 S2 heard
Sweating; Blurred vision; Pulse was low; Anxiety; Chills; This spontaneous case was reported by a pharmacist and describes the occurrence of HYPERHIDROSIS (Sweating), VISION BLURRED (Blurred vision), HEART RATE DECREASED (Pulse was low), ANXIETY (Anxiety) and CHILLS (Chills) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 immunization.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, the patient experienced HYPERHIDROSIS (Sweating), VISION BLURRED (Blurred vision), HEART RATE DECREASED (Pulse was low), ANXIETY (Anxiety) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (Sweating), VISION BLURRED (Blurred vision), HEART RATE DECREASED (Pulse was low), ANXIETY (Anxiety) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
My arm was sore. Exactly 7 days later I got a hot red welt on my arm about 2inch in diameter . I had my Dr. look at it and she wasn't concerned.  I used Hydrocortisone cream and went away in about 24 hours.
blisters around the injection side; sensitive move up and down, is between elbow and the shot; almost feel like a sun burn and touch it and hurts; blister in different areas; redness; high pressure sensitivity on her arm; development a rash and had bruise that went down to her hand and now is on her finger; development a rash and had bruise that went down to her hand and now is on her finger; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (high pressure sensitivity on her arm), RASH (development a rash and had bruise that went down to her hand and now is on her finger), VACCINATION SITE BRUISING (development a rash and had bruise that went down to her hand and now is on her finger), VACCINATION SITE VESICLES (blisters around the injection side) and BLISTER (blister in different areas) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     "No medical history was provided by the reporter.".  Concomitant products included DESVENLAFAXINE SUCCINATE (PRISTIQ) for Antidepressant therapy, POTASSIUM CITRATE for Kidney stone.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, the patient experienced LIMB DISCOMFORT (high pressure sensitivity on her arm), RASH (development a rash and had bruise that went down to her hand and now is on her finger) and VACCINATION SITE BRUISING (development a rash and had bruise that went down to her hand and now is on her finger). On 20-Apr-2021, the patient experienced BLISTER (blister in different areas) and ERYTHEMA (redness). On an unknown date, the patient experienced VACCINATION SITE VESICLES (blisters around the injection side), VACCINATION SITE MOVEMENT IMPAIRMENT (sensitive move up and down, is between elbow and the shot) and PAIN (almost feel like a sun burn and touch it and hurts). At the time of the report, LIMB DISCOMFORT (high pressure sensitivity on her arm), RASH (development a rash and had bruise that went down to her hand and now is on her finger), VACCINATION SITE BRUISING (development a rash and had bruise that went down to her hand and now is on her finger), VACCINATION SITE VESICLES (blisters around the injection side), BLISTER (blister in different areas), ERYTHEMA (redness), VACCINATION SITE MOVEMENT IMPAIRMENT (sensitive move up and down, is between elbow and the shot) and PAIN (almost feel like a sun burn and touch it and hurts) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication include Thyroid medicines in the morning.
back started itching; patient looked at her back and has darkish colored spots, the spots the texture of the skin has changed; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (back started itching) and SKIN TEXTURE ABNORMAL (patient looked at her back and has darkish colored spots, the spots the texture of the skin has changed) in a 55-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, the patient experienced PRURITUS (back started itching) and SKIN TEXTURE ABNORMAL (patient looked at her back and has darkish colored spots, the spots the texture of the skin has changed). At the time of the report, PRURITUS (back started itching) and SKIN TEXTURE ABNORMAL (patient looked at her back and has darkish colored spots, the spots the texture of the skin has changed) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.  No treatment medication was reported.
Blood clot / deep vein thrombosis in left leg developed less than one month after 2nd dose. Acute pain behind left knee, muscle ache radiating through calf to foot. Swelling. Warm to touch. Felt like a pulled muscle for a week before doctor visit.
Resident was administered a second Moderna Bivalent Booster vaccine on 10/18/2022. Resident had already recived a Moderna Bivalent Booster on 09/14/2022. Physicain and resident were notified immedialty of the administration error. No adverse reactions hav been noted following administration.
Initial unsolicited report received from a physician on 27-Nov-2017. This case involves a 02-month-old female patient who was vaccinated with a 0.5 mL dose of ACTHIB (single dose, batch number: UI726AA, expiry date: 19-Nov-2017, dose in series and site of the administration were not reported) intramuscularly on 22-Nov-2017. The patient's medical history was not reported. The patient received PEDIARIX, PCV13, and Rotavirus vaccine concomitantly. On 23-Nov-2017, one day (reported as next day) post vaccination, the mother reported that the infant's appetite was decreased by 2 ounces, she had some diarrhea and was less active initially. It was also a case of actual medication error due to expired vaccine used. Relevant lab details were not reported. It was not reported if the patient received any corrective treatment. Dr. stated she was seeing the infant in 2 days for a recheck. On 27-Nov-2017, her symptoms (decreased appetite) was resolved with the exception of some loose stools. The outcome of the event loose stools was recovering. It was reported that the physician was seeing the patient in 2 days for a recheck. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. List of documents held by sender: none.
patients received the 0.5ml dose; symptoms of a sore throat; Cold Symptoms; mild fever; body aches; This spontaneous case was reported by a nurse and describes the occurrence of OROPHARYNGEAL PAIN (symptoms of a sore throat), NASOPHARYNGITIS (Cold Symptoms), ACCIDENTAL OVERDOSE (patients received the 0.5ml dose), PYREXIA (mild fever) and MYALGIA (body aches) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Nov-2021, the patient experienced PYREXIA (mild fever) and MYALGIA (body aches). On 23-Nov-2021, the patient experienced OROPHARYNGEAL PAIN (symptoms of a sore throat) and NASOPHARYNGITIS (Cold Symptoms). On an unknown date, the patient experienced ACCIDENTAL OVERDOSE (patients received the 0.5ml dose). At the time of the report, OROPHARYNGEAL PAIN (symptoms of a sore throat), NASOPHARYNGITIS (Cold Symptoms), PYREXIA (mild fever) and MYALGIA (body aches) outcome was unknown and ACCIDENTAL OVERDOSE (patients received the 0.5ml dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.   This case was linked to MOD-2021-396492, MOD-2021-403159 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-Dec-2021: Secondary reporter added
sore arm; Vaccine exposure during pregnancy; This spontaneous pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) and PAIN IN EXTREMITY (sore arm) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (compazine), Asthma since 1994 and Hypertension since 2016.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 13-Aug-2020 and the estimated date of delivery was 20-May-2021. On 13-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-first week of the pregnancy.  On 13-Jan-2021, EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Sep-2020, Pregnancy test: positive (Positive) positive. On 12-Dec-2020, Ultrasound scan: normal (normal) Normal. On 30-Dec-2020, Ultrasound scan: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       ON 13jan2021, the patient reported that she experienced symptoms of pain in extremity and exposure during pregnancy. Follow up information was provided by the patient who reported that she had no adverse reactions related to her pregnancy.   No treatment information was provided  No concomitant information was provided   Most recent FOLLOW-UP information incorporated above includes: On 30-Jun-2021: added
eyes were running; Sinuses were super bad; This spontaneous case was reported by a consumer and describes the occurrence of LACRIMATION INCREASED (eyes were running) and SINUSITIS (Sinuses were super bad) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced LACRIMATION INCREASED (eyes were running) and SINUSITIS (Sinuses were super bad). At the time of the report, LACRIMATION INCREASED (eyes were running) and SINUSITIS (Sinuses were super bad) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.
It was reported that a 4 year old pt (3 of 3) received a Tripedia vaccination. Reportedly, sometime after the vaccination, the pt developed a 3" local reaction at the injection site. Further information is requested. From additional correspondence received on 4/26/01, it was reported that the pt received the Tripedia as well as an IPOL and a MMR vaccination on 3/25/01. The pt reportedly recovered from the adverse event. This case is closed.
Approximately 20 minutes after receiving vaccination patient begin to have nausea, feeling of heart racing and chest discomfort
pain in throat; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program. A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiration were not reported), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient had pain in throat on an unspecified date and would like to reschedule the second dose of the vaccine. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
I am reporting this simply for CDC data collection pruposes. I received my first dose on Dec. 23, 2020 - sore arm. No other adverse reactions.  2nd dose - Jan. 18th, 2021 at 0900. 7:30 yesterday evening,  I crashed and burned. I don?t think that I have ever felt so unwell; uncontrollable shaking, chills, and body aches. I had such a bad headache that I could barely lift my head off of my pillow. This lasted all night.  I had to sit on the floor of the shower this morning due to lightheadedness and nausea. I continue to feel general body aches,chills and malaise; though not nearly as bad as last night. The symptoms are slowly subsiding.
pt recv vax 5AUG97 & 8AUG97 mom reported pt had diarrhea w/no associated fever;
swollen hands to the point i can not sqeeze even pliers no hand strenghth been to PT been to Hand specialist (ortho) twice had steroid twice to try to reduce inflammation once pill form second injection at digits had vein study /ultra sound tried ex rays mri next  no hand swelling no arm swelling no weight gain only fingers tripled in size both hands had wedding ring resized from 11 to 11.5/12/12.5/13/13.5/14 Extremely painful if bumped  No one can figure it out other than possibly Moderno shot????? i will not be getting shot number 3
Pain, sometimes severe, at the injection site and a lump that comes and goes at the injection site. Pain extends from the left shoulder including the left upper chest and left upper back and radiates through the left bicep area into the elbow and forearm muscle and down to the left wrist. Pain is at times in the entire region listed or can be isolated to specific areas of the regions listed. The pain at times can be debilitating and can cause weakness, especially with push or pull activity...ie trying to open a door; there are times I have to change arms to complete the task as the arm will experience a spasm of pain and give out. There are frequent times when I experience very sore spots, painful to the the touch or with any pressure in my left upper back, left shoulder, backside of my armpit, bicep area, and forearm muscle area just below my elbow.
I had chills, headaches, body aches, arm soreness and fevers up until almost the full 48 hours. My arm is still red, swollen, and warm to touch at injection site. However my main concern is my chest. It began at about 12 hours post vaccine. I felt pressure in my chest and a weird feeling in my throat that brought on a cough. At about 18 hours when I laid down I had this tingling feeling on my tongue that was almost like I had ate something hot and burnt my tongue, but I hadn't.  After 48 hours I thought the feeling was gone. However at night I found myself unable to sleep again because the pressure in my chest when laying down was back. When I attempt to take a deep breath while laying down I have to cough. It is a dry cough. Also, the feeling in my tongue came back again...tingly amost like all my taste buds were tasting something metallic.
This case was reported by a non-health professional and described the occurrence of dizziness in a female patient who received ENGERIX B for prophylaxis. Concurrent medical conditions included anemia and blood pressure high. On 19th April 2018, the patient received the 1st dose of ENGERIX B. On an unknown date, less than a year after receiving ENGERIX B, the patient experienced dizziness. On an unknown date, the outcome of the dizziness was unknown. It was unknown if the reporter considered the dizziness to be related to ENERGIX B. Additional details were provided as follows: The age at the vaccination was not reported. The patient developed dizziness sometime after the injection. On 9th May2018, the patient was therefore advised not to receive the next dose in the series. The reporter was not the patient. The reporter advised the patient to contact the GlaxoSmithKline as she was questioning possible side effects as well as drug interactions. The reporter had no other information and did not have the patient's contact details for follow up. The reporter also did not know if the patient contacted the GlaxoSmithKline for more information.